CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform

Builds on CSL Behring's promise to patients with rare and serious diseases Gene and stem cell-based therapies complements the Company's extensive expertise in protein-based therapies Sickle cell product candidate (CAL-H) - a strategic fit for CSL Beh... Biopharmaceuticals, Mergers & Acquisitions CSL Behring, Calimmune, Cytegrity, gene therapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news